ASH 2024 Review: Key Multiple Myeloma Abstracts

Cleveland Clinic Taussig Cancer Institute

N. Callander

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

ASH 2024 Summary: Transplant in Myeloma - Key Factors in Decision-Ma…

2024 ASH Annual Meeting Insights Hub

A. Perrot

Steroid-Refractory GVHD Updates

Roswell Park Comprehensive Cancer Center

S. Holtan

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

Tandem 2025 Insights: PTCy-Based GVHD Prophylaxis After Mismatched U…

Insights from 2025 Tandem Annual Meeting

M. Al Malki

Expert Roundtable: Future Directions in Managing NDMM - MRD, CAR-T, …

MyCancerHaven

R. Vij, P. Kapoor, M. Alsina, S. Mailankody, A. Nooka, S. Tuchman

The Future of NDMM Treatment: Ongoing Trials and Key ASH 2024 Oral A…

University of Miami Sylvester Comprehensive Cancer Center

O. Landgren

Debate: The Relevance of Auto SCT for NDMM

Louisville Hematology Highlights

K. Patel, S. Usmani

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

ASH 2024 Insights: Secondary Heme Malignancies in Myeloma Post-CAR-T…

2024 ASH Annual Meeting Insights Hub

J. Waldschmidt

Managing Newly Diagnosed MM in 2024

Indy Hematology Review

S. Usmani

Acute GVHD: Demographics, Diagnosis, Pathophysiology, and Advancemen…

City of Hope

A. Salhotra

Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL…

Total Health

M. Rotta

Expert Roundtable: Maintenance Strategies in TE NDMM - Treatment App…

MyCancerHaven

R. Vij, M. Alsina, P. Kapoor, S. Mailankody, A. Nooka, S. Tuchman

ASH 2024 Insights: Optimizing Therapy Duration for Transplant-Inelig…

2024 ASH Annual Meeting Insights Hub

C. Pawlyn

The Future of Multiple Myeloma: SCT, CAR-T, and BiTE Therapy

University of Colorado Division of Hematology

K. Sidor

D-VRd With D-R Maintenance in Transplant-Eligible NDMM: PERSEUS Cyto…

Meletios Dimopoulos

ASH 2024 Insights: Ide-Cel in NDMM With Inadequate Response to 1L AS…

2024 ASH Annual Meeting Insights Hub

B. Paul